Could placental stem cell vesicles ease COVID-19?
NCT ID NCT07664696
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a single IV dose of placental stem cell vesicles (XoGlo Pro) against placebo in 64 adults with mild to moderate COVID-19. The main goal is safety, with a secondary focus on how quickly symptoms resolve. Researchers aim to see if these tiny cell particles can calm the immune response and speed recovery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
placental stem cell vesicles (XoGlo Pro)
What this could lead to
If it works, this could offer a new way to reduce COVID-19 symptoms and speed up recovery without needing long-term medication.
What could go wrong
This is an early phase trial with only 64 people, so results may not apply broadly. The treatment could cause side effects or prove no better than placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••